Studies on oncoprotein-induced feedback: Basic and therapeutic implications
癌蛋白诱导反馈的研究:基本和治疗意义
基本信息
- 批准号:10247722
- 负责人:
- 金额:$ 107.76万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2016
- 资助国家:美国
- 起止时间:2016-09-01 至 2023-08-31
- 项目状态:已结题
- 来源:
- 关键词:AllelesAttenuatedCell Death InductionCellsClinicalCombined Modality TherapyDataDependenceDevelopmentDoseDrug TargetingExposure toFRAP1 geneFeedbackGoalsKnowledgeLearningLogicMEKsMethodologyMutationNodalOncogenesOncoproteinsOutputPathway interactionsPatientsPharmaceutical PreparationsPharmacologyPhysiologicalProcessPropertyProteinsProto-Oncogene Proteins c-aktRas InhibitorReceptor ActivationReceptor InhibitionScheduleSignal PathwaySignal TransductionTherapeuticWorkantitumor effectbasecell transformationdriver mutationepigenetic regulationin vivoinhibitor/antagonistinsightmutantnovelsmall hairpin RNAsuccesstumor
项目摘要
PROJECT SUMMARY / ABSTRACT
We have established that oncoproteins which function as dysregulated components of mitogenic
signaling pathways cause marked feedback inhibition of physiologic signaling. Much of our recent work
has focused on understanding the implications of this phenomenon. Insensitivity to feedback inhibition
of receptor activation of wild type RAS is a common property of oncoproteins that activated ERK
signaling that is required for them to elevate ERK output. Second, elevated pathway output includes
elevated feedback inhibition of physiologic signaling pathways. This is a major determinant of the so-
called oncoprotein dependence of transformed cells. Third, feedback-dependent oncoprotein pathway
dependence reduces the robustness of the cell and creates a selection for mutations that activate
feedback-Inhibited pathways and restores robustness. This accounts for some of the secondary driver
mutations identified in tumors. Finally, inhibitors of oncoprotein-activated signaling have significant
antitumor activity, but also relieve feedback inhibition of physiologic mitogenic signaling pathways and
cause their reactivation. This attenuates their antitumor activity and creates a logic for inhibiting key
reactivated pathways in tumors exposed to inhibitors of oncoproteins. This strategy has had some early
clinical success and has become a paradigm for the development of rational combination therapies.
Despite these insights, we still know only few of the details of oncoprotein-induced feedback and its
relief by targeted inhibitors. We do know that these details vary as a function of tumor lineage and
which pathway component is mutationally activated. Moreover, the effects of relieving feedback also
vary depending on which node of the pathway is pharmacologically inhibited. We now plan to
comprehensively study feedback and its relief by nodal inhibitors, focusing on a few tumors and using
both methodologies biased by previous knowledge of normal signaling and unbiased shRNA screens.
We utilize selective inhibitors of PI3K, AKT, mTOR, RAF, MEK, ERK, and a novel allele-specific
inhibitor of RAS and study both short- and long-term adaptation, to determine whether some of the
effects of the latter are due to epigenetic regulation. The goal is to develop new effective combination
therapies based on these data and on in vivo studies to determine dose schedules that optimize
induction of cell death.
项目总结/摘要
我们已经证实,作为促有丝分裂素的失调成分发挥功能的癌蛋白,
信号传导途径引起生理信号传导的显著反馈抑制。我们最近的大部分工作
致力于理解这一现象的含义。对反馈抑制不敏感
野生型RAS的受体激活是激活ERK的癌蛋白的共同特性
这是它们提高ERK输出所需的信号。第二,升高的通路输出包括
生理信号通路的反馈抑制升高。这是一个重要的决定因素,
被称为癌蛋白依赖性。第三,反馈依赖的癌蛋白通路
依赖性降低了细胞的健壮性,并产生了对激活细胞的突变的选择。
反馈抑制途径并恢复鲁棒性。这说明了一些次要驱动因素
在肿瘤中发现的突变。最后,癌蛋白激活信号的抑制剂具有显著的
抗肿瘤活性,而且还减轻生理性促有丝分裂信号传导途径的反馈抑制,
导致它们重新激活。这减弱了它们的抗肿瘤活性,并创造了一种逻辑,
在暴露于癌蛋白抑制剂的肿瘤中重新激活通路。这一战略在早期已经有了一些
临床成功,并已成为开发合理组合疗法的范例。
尽管有这些见解,我们仍然只知道癌蛋白诱导的反馈及其作用的一些细节。
通过靶向抑制剂缓解。我们知道这些细节随着肿瘤谱系的变化而变化,
该途径组分被突变激活。此外,缓解反馈的效果也
取决于通路的哪个节点被抑制。我们现在计划
全面研究反馈及其缓解节点抑制剂,重点放在少数肿瘤和使用
这两种方法都受到以前对正常信号传导的了解的影响,并进行了无偏倚的shRNA筛选。
我们利用PI 3 K、AKT、mTOR、RAF、MEK、ERK的选择性抑制剂和一种新的等位基因特异性抑制剂。
RAS抑制剂和研究短期和长期适应,以确定是否有一些
后者的影响是由于表观遗传调节。目标是开发新的有效组合
基于这些数据和体内研究的治疗,以确定优化
诱导细胞死亡。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
NEAL ROSEN其他文献
NEAL ROSEN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('NEAL ROSEN', 18)}}的其他基金
Studies on oncoprotein-induced feedback: Basic and therapeutic implications
癌蛋白诱导反馈的研究:基本和治疗意义
- 批准号:
9766084 - 财政年份:2016
- 资助金额:
$ 107.76万 - 项目类别:
Studies on oncoprotein-induced feedback: Basic and therapeutic implications
癌蛋白诱导反馈的研究:基本和治疗意义
- 批准号:
9186828 - 财政年份:2016
- 资助金额:
$ 107.76万 - 项目类别:
Clinical Development of Next-Generation Antiandrogens and the Impact of PTEN Status
下一代抗雄激素的临床开发和 PTEN 状态的影响
- 批准号:
8730087 - 财政年份:2014
- 资助金额:
$ 107.76万 - 项目类别:
Developing therapeutic strategies for ERK-dependent tumors
开发 ERK 依赖性肿瘤的治疗策略
- 批准号:
8906506 - 财政年份:2013
- 资助金额:
$ 107.76万 - 项目类别:
Developing therapeutic strategies for ERK-dependent tumors
开发 ERK 依赖性肿瘤的治疗策略
- 批准号:
8741950 - 财政年份:2013
- 资助金额:
$ 107.76万 - 项目类别:
Developing therapeutic strategies for ERK-dependent tumors
开发 ERK 依赖性肿瘤的治疗策略
- 批准号:
8632319 - 财政年份:2013
- 资助金额:
$ 107.76万 - 项目类别:
Development of Methodologies for the In Vivo Imaging og the Effects of Novel Inhi
体内成像方法的开发和新型 Inhi 的效果
- 批准号:
7729470 - 财政年份:2008
- 资助金额:
$ 107.76万 - 项目类别:
Development of Mechanism-Based Strategies for the Treatment of Advanced Breast Ca
开发基于机制的晚期乳腺癌治疗策略
- 批准号:
7438486 - 财政年份:2008
- 资助金额:
$ 107.76万 - 项目类别:
Project 2: Targeting the ERK Pathway in KRAS- and BRAF-Driven Lung Cancers
项目 2:针对 KRAS 和 BRAF 驱动的肺癌中的 ERK 通路
- 批准号:
10246297 - 财政年份:2007
- 资助金额:
$ 107.76万 - 项目类别:
HSP90 AS A TARGET FOR MECHANISM-BASED THERAPY FOR CASTRATION-RESISTANT PROSTATE C
HSP90 作为去势抵抗性前列腺癌基于机制治疗的靶点
- 批准号:
7147036 - 财政年份:2005
- 资助金额:
$ 107.76万 - 项目类别:
相似海外基金
A platform for rapidly generating live attenuated enterovirus vaccines
快速生成减毒肠道病毒活疫苗的平台
- 批准号:
24K02286 - 财政年份:2024
- 资助金额:
$ 107.76万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
I-Corps: Translation potential of an efficient method to generate live-attenuated and replication-defective DNA viruses for vaccine development
I-Corps:一种有效方法的转化潜力,可生成用于疫苗开发的减毒活病毒和复制缺陷型 DNA 病毒
- 批准号:
2420924 - 财政年份:2024
- 资助金额:
$ 107.76万 - 项目类别:
Standard Grant
Developing a robust native extracellular matrix to improve islet function with attenuated immunogenicity for transplantation
开发强大的天然细胞外基质,以改善胰岛功能,并减弱移植的免疫原性
- 批准号:
10596047 - 财政年份:2023
- 资助金额:
$ 107.76万 - 项目类别:
Live attenuated non-transmissible (LANT) Klebsiella pneumoniae vaccines
肺炎克雷伯氏菌减毒非传染性 (LANT) 活疫苗
- 批准号:
10742028 - 财政年份:2023
- 资助金额:
$ 107.76万 - 项目类别:
Protecting Pigs From Enzootic Pneumonia: Rational Design Of Safe Attenuated Vaccines.
保护猪免受地方性肺炎:安全减毒疫苗的合理设计。
- 批准号:
BB/X017540/1 - 财政年份:2023
- 资助金额:
$ 107.76万 - 项目类别:
Research Grant
A “Goldilocks” live attenuated poultry vaccine for Infectious Coryza
用于传染性鼻炎的“Goldilocks”家禽减毒活疫苗
- 批准号:
LP210301365 - 财政年份:2023
- 资助金额:
$ 107.76万 - 项目类别:
Linkage Projects
A novel live-attenuated Zika vaccine with a modified 5'UTR
一种带有改良 5UTR 的新型寨卡减毒活疫苗
- 批准号:
10730832 - 财政年份:2023
- 资助金额:
$ 107.76万 - 项目类别:
Combating melanoma with an attenuated bacterial therapeutic
用减毒细菌疗法对抗黑色素瘤
- 批准号:
10659841 - 财政年份:2023
- 资助金额:
$ 107.76万 - 项目类别:
Investigating Host and Viral Factors for Improved Design of Future Live Attenuated Vaccines for IBV
研究宿主和病毒因素以改进未来 IBV 减毒活疫苗的设计
- 批准号:
BB/V016067/1 - 财政年份:2022
- 资助金额:
$ 107.76万 - 项目类别:
Research Grant
L2M NSERC-Bioengineering attenuated Sclerotinia sclerotiorum strains as bioherbicide for cereal production and lawn management
L2M NSERC-生物工程减毒核盘菌菌株作为谷物生产和草坪管理的生物除草剂
- 批准号:
576545-2022 - 财政年份:2022
- 资助金额:
$ 107.76万 - 项目类别:
Idea to Innovation